Resources for healthcare professionals and patients
Use the information below to learn why TAKHZYRO is a proven preventive treatment for HAE and how to create effective HAE management plans for your patients. You'll also find resources you can share with your patients to help them start and stay on TAKHZYRO.
Watch as experts on HAE discuss disease management and treating patients with TAKHZYRO.
Uncovering the impact of hereditary angioedema
Because HAE is unpredictable, patients may live in fear of their next attack.1 Watch as a real TAKHZYRO patient speaks with an HAE expert about the burden of HAE.
View Transcript
Kyle: Thank you.
Dr Douglas Lotz: Appreciate it. So Kyle, how have you been doing with your HAE since the last time we spoke?
Kyle: I'm doing well. I'm still happy with the preventive treatment. When I was younger, my attacks were more frequent and they used to impact my ability to go to work and school.
Dr Douglas Lotz: I remember you telling me that.
Kyle: My job is so physical, but now I'm outside in the heat all day doing repetitive motion. I'm not thinking as much about a potential HAE attack, and that's good, because stress is one of my biggest triggers.
Dr Douglas Lotz: That's great to hear. You know, since you first started taking TAKHZYRO, you've seen results from your preventive treatment and we've seen your attacks reduce significantly. I'm hopeful that will continue.
Kyle: Well, I have you to thank for that. It helped that you listened to what I was going through, you didn't just ask about my symptoms.
Dr Douglas Lotz: I remember when we first met five years ago, you told me one of your major concerns about HAE was how the unpredictability of attacks was affecting you.
Kyle: It was. Before I was diagnosed at 24, so many doctors told me I had food allergies and gave me steroid, which didn't help. Even after I was diagnosed, it took a long time to feel better.
Dr Douglas Lotz: I'm sure.
Kyle: Years ago, I had a swell that moved from my face to my neck. I arranged to have acute medication on hand at the local hospital. When I arrived having an attack, they told me the medication had expired. That's when I felt completely on my own when it came to managing my HAE. I went home and administered my own unexpired medication.
Dr Douglas Lotz: Wow, I can only imagine what that must've been like. You know, I've heard from many patients that they've struggled to trust others to manage their condition.
Kyle: The first doctor I saw didn't really know much about HAE. I was taking a preventative treatment, but it wasn't working for me. When I heard you speak about HAE and the other available preventive treatment options, I was encouraged to start asking questions and advocate more for myself.
Dr Douglas Lotz: Kyle, one of my goals is to help you get to a place where you're thinking less about your HAE attacks. As physicians, we need to discover barriers that patients are facing and help to shift them.
Kyle: You definitely did that for me. You also asked questions that other doctors didn't ask.
Dr Douglas Lotz: It's helpful to understand patients' experiences with attacks and how they've treated them, but it's important to dig deeper. How are patients really feeling on a daily basis? How are they impacted by their disease? What are their personal goals for their care and are they meeting them? One way we can do this is by using a disease burden assessment tool.
Kyle: That's a helpful tool.
Dr Douglas Lotz: It really is, and we need to keep asking questions, listening and learning so we can make informed decisions with the patient. Decisions that are guided by clinical data, experience, and the patient's overall goals.
Kyle: This approach made a world of difference and it's how we arrived at TAKHZYRO. It helped me manage my HAE attacks. We've also discussed the potential risks, including the most common side effects.
Dr Douglas Lotz: And you are not the only one. Many of my patients have told me they're seeing positive results since starting on TAKHZYRO.
Kyle: The first conversation we had about preventive treatment came when I was struggling to make a change. If it wasn't for you, I'd still be stuck where I was. As we've discussed in the office, TAKHZYRO's not just for people with frequent HAE attacks, it can be considered for anyone who has HAE.
Dr Douglas Lotz: Yes, every patient with HAE is absolutely appropriate to be considered for effective preventive treatment. The possibility of a life-threatening laryngeal event or a debilitating swell is why it is so important that we continue to have these conversations.
Kyle: I can't thank you enough, Dr Lotz, for everything.
Dr Douglas Lotz: Thank you, Kyle. What do you have in there?
Narrator: TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.
No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information at TAKHZYRO.com/hcp.
Because HAE is unpredictable, patients may live in fear of their next attack.1 Watch as a real TAKHZYRO patient speaks with an HAE expert about the burden of HAE.
Long-term HAE management
Watch as 2 HAE experts break down best practices used by doctors to understand the impact of HAE as well as to create long-term HAE management plans for their patients.
View Transcript
Dr Cristina Ramos: Yeah.
Dr Daniel Soteres: ... on cold sores.
Dr Cristina Ramos: Thank you.
Dr Daniel Soteres: Delicious. Thanks.
Dr Cristina Ramos: So Danny, I just had an interesting conversation with one of my patients with HAE that I think you can relate to. This patient has been resistant to preventive therapy for a while. She's been downplaying her HAE attacks saying things like, "Oh, it's just a hand swell, no big deal."
Dr Daniel Soteres: Ah, yes, this sounds familiar.
Dr Cristina Ramos: But today, she came in with her husband and he said she was having attacks every week. She finally realized the impact HAE was having on her and her family and decided to start preventive treatment. For the longest time, she had minimized her condition.
Dr Daniel Soteres: I have patients who may have attacks that impact their daily lives. One patient of mine is a waitress. She had a hand swell one time during work. Imagine her job that day. Serving food, clearing tables with a hand swell. She downplayed the attack, but I knew it was affecting her. I let her know it was very helpful that she told me about it, because it clarified to me that she could likely benefit from preventive therapy. I didn't want her to downplay the discomfort she was experiencing, and I didn't want her normalizing an attack that would cause her to miss a day of work. Many patients make sacrifices they don't have to.
Dr Cristina Ramos: I agree. It's important for us to understand how HAE affects patients' daily activities. We shouldn't just ask, "When was the last time you had an attack?" We also need to ask, "Did you miss something important due to an HAE attack?" That helps patients consider how much the disease may be affecting them and whether we need to explore another treatment approach.
Dr Daniel Soteres: Exactly. Tracking how often they use acute treatment is also beneficial. One of my patients kept a log for a year. But this isn't something most patients will do. I ask them at clinic appointments, sit back, reflect on their attacks over the past few months. I give them a pen, piece of paper, and a calendar, and I leave them alone while I see another patient, come back a few minutes later to see what they've come up with.
Dr Cristina Ramos: That's a really helpful way to have patients think about their attack history. How do you approach patients when they're first diagnosed with HAE?
Dr Daniel Soteres: Well, for newer patients, it's important not to pressure them into making treatment decisions at the first visit. HAE is a lifelong disease, and I want patients to know that I'm invested in being a guide for them throughout that whole journey.
Dr Cristina Ramos: Yes, definitely. Checking in every few months is essential when establishing a long-term management plan. I've seen that some patients will consider prevention when their attacks increase, but others don't. Perhaps they worry it will interfere with their daily routines?
Dr Daniel Soteres: That's why we need to balance conversations about treatment options with patients' personal concerns and their health literacy. I treat patients of all ages, children, adolescents, and adults through our understanding of the disease. And their options are quite different and they change over time.
Dr Cristina Ramos: Sometimes I ask, "Do you prefer an injection that you can administer every couple of weeks? Or do you want to take something every day?" Above all, patients need to feel comfortable with their choices.
Dr Daniel Soteres: Ooh, I really like that approach. You mind if I use it in my practice?
Dr Cristina Ramos: Not at all, Danny. And I think I'm going to use the tracking method you mentioned also.
Dr Daniel Soteres: I discuss all the options with my patients and try to take into consideration their goals and perspectives. When it comes to TAKHZYRO, from my experience, patients get started on it and after a period of time they see results. I don't have too many patients calling after several months and saying, "I'm having frequent attacks."
Dr Cristina Ramos: You know, I recognize these are individual patient experiences, and every patient's experience is different. TAKHZYRO has been studied in the broadest range of patients age two years and older. And I found that many of my patients have seen a decrease in their HAE attacks, including patients with an infrequent attack history.
Dr Daniel Soteres: I appreciate that my patients don't let their HAE define them. My experience prescribing TAKHZYRO in my practice has shown positive results for them. Reaching steady state within the first few months is something I explain to my patients when they begin treatment to set expectations. I always tell patients that breakthrough attacks can happen, but it's important to stick with their dosing schedule. And they do, even when they go on camping trips or vacations. Treating patients every two or four weeks can give them back their time.
Dr Cristina Ramos: Which is why every two- or four-week dosing can be a plus for patients.
Dr Daniel Soteres: Adult patients are not the only ones who should consider preventive therapy. One of my 13-year-old patients saw enough of a reduction in attacks after starting on TAKHZYRO that her mother felt more comfortable to consider sending her to another state to perform with the school orchestra. And of course, the three of us all discussed the potential risks of TAKHZYRO, including the most common side effects.
Dr Cristina Ramos: Also, thanks to the expanded indication, we can offer TAKHZYRO to patients from 2 to less than 12 years of age.
Dr Daniel Soteres: Patient experiences like these help me feel like I'm supporting my patients as best I can.
Dr Cristina Ramos: I completely agree. When I see older patients with HAE who haven't had access to preventive treatment for part of their lives, it's so satisfying to be able to provide a treatment option like TAKHZYRO.
Dr Daniel Soteres: Yes, and it's also nice to know that TAKHZYRO is the number one prescribed HAE preventive treatment.
Dr Cristina Ramos: Danny, this was helpful. Thanks for catching up with me today.
Dr Daniel Soteres: Of course. Let's make a plan to talk like this more often.
Narrator: TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.
No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information at TAKHZYRO.com/hcp.
Watch as 2 HAE experts break down best practices used by doctors to understand the impact of HAE as well as to create long-term HAE management plans for their patients.
The right patient for TAKHZYRO
Dive in and learn more about who might be the right patient for TAKHZYRO. By examining the characteristics of their own HAE patients, as well as looking at the HAE community at large, 2 HAE experts will discuss what makes a patient right for TAKHZYRO.
View Transcript
Dr Michael Manning: I was just thinking about how far we've come for patients with HAE in the last 15 years. A few weeks ago, one of my patients who is on preventive therapy went hiking with his father. This is something he used to choose to avoid in case he would have an HAE attack.
Dr Douglas Lotz: I agree. Preventive therapy has been impactful for many of my patients as well.
Dr Michael Manning: I found that my patients with HAE who really know their triggers and go out of their way to avoid them could likely benefit from preventive treatment, including those who recognize stress is a trigger. When job or family pressures come into play, the last thing they want is an HAE attack added on.
Dr Douglas Lotz: It's why it's so important to have the right conversations in order to uncover their specific situations and to address their unique goals. I wouldn't want my patients avoiding things out of concern for their next attack.
Dr Michael Manning: You know, I'll ask them things like, "Are there activities you're missing out on? Do you think about your next attack?" Sometimes, a patient has an attack only once in six months, but it may still cause disruption. I don't want my patients missing events. Even for a patient with very few attacks per month, if they're anticipating having one, I recommend they consider a preventive medication like TAKHZYRO.
Dr Douglas Lotz: You hit on a really good point there. No matter what a patient's HAE attack frequency is, the unpredictability of those attacks can be challenging. Patients may ask themselves, "When is my next attack going to happen? Is it going to be life-threatening?"
Dr Michael Manning: I've also had patients who didn't realize their symptoms were HAE attacks. One time, the wife of one of my patients mentioned that her husband was having stomach pains several times a month. He didn't realize it was his HAE attacks until I put him on preventive treatment and his attacks became less frequent. But I recognize these are his experiences and every patient's experience is different.
Dr Douglas Lotz: Mike, what do you do to anticipate situations like the one you just mentioned?
Dr Michael Manning: You know, Doug, I tend to ask patients a lot of questions such as, "Are you having any recurring issues that may seem mild, but pop up now and then?" I ask about areas of the body where HAE attacks may typically occur even if the patient hasn’t experienced swelling at that location.
Dr Douglas Lotz: That's a really good point. One additional consideration I have when looking at treatment options for patients is the route of administration. TAKHZYRO is a subcutaneous injection. How do you identify which patients are right for TAKHZYRO? Do you consider disease severity?
Dr Michael Manning: You know, I don't label a patient with HAE as mild, moderate, or severe, because if you label a patient as mild, what does that do? That sets you up for complacency. Any patient with HAE can have a mild, moderate, or severe attack. And HAE symptoms can change over time. It depends on how it's affecting that person.
Dr Douglas Lotz: Right. We don't have mild, moderate, or severe HAE. And I'll fight tooth and nail to never have a metric like that because we can't ever predict that the next HAE attack will be like the last one.
Dr Michael Manning: Agreed. Using terms like mild or less severe to describe HAE can be misleading. The disease is potentially life-threatening for all HAE patients.
Dr Douglas Lotz: From my point of view, the ideal patient for TAKHZYRO is really any patient who has HAE. It's for those who want to move away from infusions and for those who don't have the time or desire to treat themselves several times a week. Most of my patients, if they're six years of age or older, and have been well controlled for more than six months, meaning attack free, prefer the flexibility and option of dosing every four weeks. Of course, I always discuss with my patients the potential risks of TAKHZYRO, including the most common side effects.
Dr Michael Manning: That pediatric indication for children as young as two years of age gives us the possibility to help younger patients prevent HAE attacks.
Dr Douglas Lotz: Yes, it is great that younger patients won't have to wait to begin preventive therapy.
Dr Michael Manning: Thanks, Doug, for sharing your experiences with me.
Dr Douglas Lotz: Thank you, Mike. It's great seeing you again.
Dr Michael Manning: Great seeing you too. Thanks for joining me.
Dr Douglas Lotz: Oh, thank you.
Dr Michael Manning: Thank you so much.
Dr Douglas Lotz: Great.
Dr Michael Manning: Yeah.
Narrator: TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.
No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information at TAKHZYRO.com/hcp.
Dive in and learn more about who might be the right patient for TAKHZYRO. By examining the characteristics of their own HAE patients, as well as looking at the HAE community at large, 2 HAE experts will discuss what makes a patient right for TAKHZYRO.
Cultivating lifelong relationships
HCPs can play a big role in keeping patients engaged throughout their entire treatment journey: discussing positive outcomes, working through breakthrough attacks, celebrating milestones, staying committed, and more. Watch as a real TAKHZYRO patient speaks with an HAE expert about all the ways they can stay connected throughout their treatment journey.
View Transcript
Dr William Lumry: ... exactly.
Pam: You never know what you're going to be doing. Oh, hi.
Dr William Lumry: Thank you, Kevin.
Pam: It looks great, thank you.
Dr William Lumry: Appreciate it. Pam, it's great to see you. The last time we talked, you were planning a family party, I think, right?
Pam: We did. Everyone had a great time and I wasn't worried about experiencing an HAE attack.
Dr William Lumry: That's great to hear. I remember you sharing stories about avoiding certain events because of concern about having an attack, and how the unpredictability of attacks impacted you.
Pam: I think those conversations really helped you understand what I was going through and helped me get on the right preventive treatment.
Dr William Lumry: I've heard from many of my patients that preventive therapy has helped them. I'm glad it's worked that way for you. How are your daughters doing?
Pam: They're wonderful. One just came back from a trip abroad. Thanks for preparing us in case she had an attack while she was gone.
Dr William Lumry: Of course, I'm always happy to help patients plan ahead to reduce the possibility of an HAE attack.
Pam: Well, thanks to you, the timing worked out, so she was between doses during her vacation and she didn't need to pack her preventive medication, so she had a really great time.
Dr William Lumry: Good for her.
Pam: I'm just so grateful that my girls and I have someone like you who's been a part of our lives for over 10 years and who really knows us and understands what we're going through with our HAE.
Dr William Lumry: That's why we do what we do. You know, I'm glad I was able to prescribe the three of you TAKHZYRO and that it's been effective for you. You know, HAE attacks affect every patient differently, so each patient needs to be treated uniquely. When I talk about treatment options, we discuss their expectations regarding efficacy, preferences for the route of administration, potential side effects, safety information, the approval process, and so on and so on. That helps them decide which treatment might be best for them.
Pam: There is a lot to consider.
Dr William Lumry: There really is. And on top of that, as you know, HAE can change over time. It can become more or less severe, as a result, a patient's needs may change too, so healthcare providers need to keep checking in and continuing to ask the right questions.
Pam: You were the first physician, after years of searching, who listened to me instead of just talking to me, and you asked how I was really feeling, what was going on in my life, what I wanted to accomplish, how my HAE affected me, and how I felt between attacks.
Dr William Lumry: And to your credit, you answered all the questions. You know, not all patients are comfortable talking about their lives in that way, but it helps paint a fuller picture so together we can figure out the best way to manage their HAE attacks.
Pam: It's been a long journey for me to feel like my HAE doesn't define me.
Dr William Lumry: And that journey you talk about is ongoing, Pam. It doesn't end once you're on a preventive treatment you're happy with. We discuss updates on how you're feeling, if anything has changed with your HAE, and if the treatment is still meeting your goals.
Pam: I can't begin to tell you how much that means to me and my family.
Dr William Lumry: I want my patients to be engaged every step of the way and empowered to feel like they have choices, and I want them to trust that our office will be true partners with them throughout their journey.
Pam: I totally feel that and I know my daughters do too.
Dr William Lumry: That's great. And TAKHZYRO offers patients every-two-week dosing with the option of going to every four weeks if things are well controlled, which I hope has helped as well.
Pam: TAKHZYRO has made a difference in our lives by reducing HAE attacks. I have to tell you, I'm so relieved that there's something available that has been proven to help reduce the frequency of those attacks.
Dr William Lumry: I am too, and I appreciate how you keep me informed about your progress, not just with TAKHZYRO, but with everything going on in your life. It helps us make sure we can keep up with your routine.
Pam: Well, you've made yourself so available to me and my family over the years, and you've gone above and beyond to take care of us. Thank you for everything that you continue to do for those of us with HAE.
Dr William Lumry: Thank you, Pam. I'm glad we got a chance to visit today.
Narrator: TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.
No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information at TAKHZYRO.com/hcp.
HCPs can play a big role in keeping patients engaged throughout their entire treatment journey: discussing positive outcomes, working through breakthrough attacks, celebrating milestones, staying committed, and more. Watch as a real TAKHZYRO patient speaks with an HAE expert about all the ways they can stay connected throughout their treatment journey.
What do the 2020 US HAEA guidelines mean to patients?
See what patients think about TAKHZYRO being recommended as a treatment option by a trusted organization.
HAEA=Hereditary Angioedema Association.
View Transcript
JACK: The HAEA is a nonprofit advocacy and research group that helps people with HAE and it's an organization that I trust. Their website is one of the first ones I tell people to visit if they want to learn about the condition.
KELLY: The HAEA worked with experts in the medical community to create HAE treatment recommendations. These guidelines recommend that everyone with HAE talk to their doctor about long-term preventive treatment in order to find out if it's right for them.
ANDREW: My HAE attacks weren't always frequent, but they could certainly be unpredictable. I thought it was enough to just take my on-demand medication when I needed it and just push through the attack. But talking to my doctor and understanding the guidance from the HAEA about long-term prevention really helped me turn a corner in how I manage my attacks.
DENNIS: It definitely gives me confidence knowing that they recommend TAKHZYRO as a preventive option. It means TAKHZYRO is one of the preventive treatments you should talk to your doctor about.
SORAYA: The HAEA recommendation makes me think I'm taking a medication that is recommended in the HAE community and I can feel good about that.
NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age. TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.
See what patients think about TAKHZYRO being recommended as a treatment option by a trusted organization.
HAEA=Hereditary Angioedema Association.
How do patients decide TAKHZYRO is right for them?
See why patients trust TAKHZYRO to help reduce their HAE attacks.
View Transcript
DENNIS: My doctor told me about TAKHZYRO, and my wife and I did some research. At the end of the day, I trust that my medical team and what they told me. After discussing the potential risks and the possibility of fewer HAE attacks, we decided it was the right treatment to take. And it's definitely made a big difference for me. I'm glad I listened.
KELLY: Seeing the clinical data and how effective TAKHZYRO was got my attention. It told me that this is a clinically proven treatment to help prevent HAE attacks, and that gave me the confidence to start.
JACK: For me, taking TAKHZYRO once every two weeks means it's not something I need to think about often. Plus, it's subcutaneous, which means it's injected under the skin, not in the vein. That feels manageable for me.
ANDREW: The actual injection takes about a minute, and then I'm free from thinking about my next dose for a few weeks.
SORAYA: I can inject myself, and it takes about a minute. It's an important thing I can do for myself to help reduce the frequency and severity of my HAE attacks.
NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age. TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.
See why patients trust TAKHZYRO to help reduce their HAE attacks.
What is injecting TAKHZYRO like for patients?
Patients taking TAKHZYRO share their tips.
View Transcript
JACK: Injecting TAKHZYRO has not been a problem for me. For one, I only have to inject it once every two weeks. Plus, it's subcutaneous, which means it's under the skin, not in the vein. That feels manageable for me.
KELLY: Being able to switch up injection sites is a big plus for me personally, that and the fact that I can go two weeks between injections.
SORAYA: After I was trained how to do it, injecting has been manageable for me. I can do it myself, and it takes about a minute. It's an important thing I can do for myself to help reduce the frequency and severity of my HAE attacks.
DENNIS: I was having a hard time prepping the medication the way the OnePath nurse showed me. Luckily, my wife was able to do it, and I just watched her a few times. And now I am proud to say I can do it myself.
ANDREW: The actual injection takes about a minute, and then I'm free from thinking about my next dose for two weeks.
NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age. TAKHZYRO may cause serious side effects including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms, wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash and/or hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant and breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding or plan to breastfeed.
NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.
Patients taking TAKHZYRO share their tips.
